Significance and Limitations of the p Value  by Dick, F. & Tevaearai, H.
Education Section: Associate Editors Florian Dick and Gert de Borst Eur J Vasc Endovasc Surg (2015) 50, 815EDUTORIALSigniﬁcance and Limitations of the p Value1078
Elsevie
httpKeywords: Methodology, Interpretation of science, StatisticsIn research authors, journals, and readers all aim to produce, publish, and
consume signiﬁcant (worthwhile) content. Thereby, an assumed measure of
“signiﬁcance” (i.e. p < .05) is easily mistaken as a handy indicator. However,
the .05 threshold is completely arbitrary and p values as such are inappro-
priate to guide clinical or scientiﬁc decision making. p stands for (statistical)
probability and not for (clinical) certainty; thus, it characterizes individual
comparisons statistically but without clinical interpretation. Signiﬁcance is
thereby deﬁned very narrowly and must not be confused with clinical rele-
vance, generalisability or even meaning of ﬁndings.
Two biological observations are never identical, but will always show a
natural degree of variation even if the same samplewas evaluated twice under
identical conditions. The main challenge lies in differentiating whether the
observed difference reﬂects such “background noise” or a real difference
(attributable, for instance, toan intervention).Thep value is a directmeasureof
the probability that the observed difference is a simple chance ﬁnding (i.e.
unreal). If this probability is very small, for instance less than 5%, then the
assumption of a true difference (or treatment effect) may seem justiﬁed.
Importantly, the 5% threshold is not absolute but relies on convention
only. There is no critical difference between p ¼ .045 and p ¼ .055: the
likelihood of a chance ﬁnding differs just by 1%. At other times, a remaining
uncertainty of 5% may be unacceptably high: a car with a known 5% risk of
brake failure would probably not be licensed! A p value provides at best a
crude orientation regarding the probable realness of speciﬁc group differ-
ences, but is too simplistic to explain the “big (clinical) picture”.
Speciﬁcally, p values must not be mistaken as a substitute for critical
appraisal in many crucial aspects.
(1) A p value does not indicate whether the described comparison was
justiﬁed (e.g. whether the compared groups were comparable to begin
with). This fundamental precondition must be ascertained within the study
design. For instance, randomised controlled experiments approach the
ideal of unbiased study group comparability best, but to a certain extent
this can be emulated by stratiﬁed or confounder adjusted observational
studies.
(2) A p value ignores whether the selected statistical test was appro-
priate. The correct choice depends on the data to be assessed, the sample
size, the comparative concept, and the outcome format, all of which must
be checked during critical appraisal.
(3) As elaborated, the threshold at .05 leaves signiﬁcant uncertainty,
whether the assumption of a difference (or treatment effect) is, in fact,
correct (alpha error). The need for additional safety margins (i.e. a lower
degree of uncertainty, for instance p < .01) depends on the clinical context.
Conversely, as p values refer to speciﬁc samples only, a “non-signiﬁcant”
p > .05 does not exclude relevant effects of an intervention in clinical
reality (so called beta error): absence of proof is not proof of absence!
(4) A p value depends on the sample size: the larger the sample, the
smaller the associated p value and the higher the risk of “accidental” sig-
niﬁcance at the 5% threshold. Remember, p values do not reﬂect the
clinical relevance of a ﬁnding, even if the underlying difference is real. A
clinically modest treatment effect may appear “signiﬁcant” when tested in
a large enough (“overpowered”) sample. If, for instance, a trial reported a
real antihypertensive drug effect (p < .001),1 the clinical decision whether
to expose your patient to any potential adverse effects (for the beneﬁt of a-5884/ 2015 European Society for Vascular Surgery. Published by
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://dx.doi.org/10.1016/j.ejvs.2015.07.026diastolic pressure reduction by 4.4 mmHg at 8 weeks) should not be driven
by the p value. Clinical relevance must be appraised by appropriate mea-
sures such as effect size (e.g. relative risk, absolute difference or number
needed to treat) with estimated precision (i.e. conﬁdence intervals). The
latter represents an important alternative for the assessment of statistical
(and clinical) signiﬁcance. Conversely, small (“underpowered”) study sam-
ples must not be used to dismiss treatment effects (see (3)): a power
calculation is always required for adequate appraisal.
(5) A p value does not indicate whether the study design was predeﬁned
or the analysis plan adopted before data inspection. Therefore, p values
ignore biased selection of patients or study periods just as they ignore,
statistical ﬁshing expeditions (i.e. multiple hypothesis testing). Conse-
quently, explorations should always be validated in hypothesis driven in-
vestigations in different study samples.
(6) A p value, as such, never indicates causality. Other criteria including
chronological sequence, biological plausibility, and exclusion of confound-
ing effects must be met before a causal relationship may be assumed.
And (7), a p value refers to summary statistics of speciﬁc study samples
only. The application of study ﬁndings to individual patients is only justiﬁed
after appraisal of their external validity (i.e. generalisability).
Clearly, p values represent a precious ﬁrst aid for orientation. However,
they must be carefully interpreted against study design, sample size,
comparability of study groups, and appropriateness of statistical tests, and
be pondered against clinical signiﬁcance. Categorisation (e.g. p < .05,
p ¼ n.s., etc.) obscures the interpretations of this continuous measure and
is unacceptable. At any rate, comprehensive appraisal of scientiﬁc infor-
mation must go beyond a single indicator. It is the responsibility of anyone
dealing with summary statistics to assure that study question and design,
statistical approach, and presentation of results are sound before accepting
or dismissing reported ﬁndings. A p value < .05 may be signiﬁcant sta-
tistically, but never proves clinical signiﬁcance.
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